Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Target Audience: The intended audience for the activity is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Review current guidelines on treat-to-target approach in inflammatory bowel disease (IBD).
- Assess and monitor disease severity in patients with IBD, using evidence-based modalities that improve the care of established and new patients.
- Select treatment strategies in mild to moderate IBD that safety deliver the appropriate therapy and improve patient outcomes.
- Analyze the use of biologics, combination therapies, and emerging agents with novel mechanisms of action in patients with IBD refractory to current therapeutic options.
- Incorporate the use of biomarkers and other therapeutic regimens that may improve patient outcomes and mucosal healing in IBD.
- Apply therapeutic drug monitoring as needed to optimize the management of IBD.
Activity Chair:
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, PA
Faculty:
Benjamin Cohen, MD, MAS
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Jean-Frédéric Colombel, MD
Director of Feinstein IBD Clinical Center &
Helmsley Charitable Trust IBD Center
Icahn School of Medicine
Mount Sinai Hospital
New York, NY
Peter D.R. Higgins, MD, PhD, MSc
Professor of Internal Medicine
University of Michigan
Ann Arbor, MI
Dermot McGovern, MD, FRCP, PhD
Director, Translational Medicine
Inflammatory Bowel Disease Center and Immunobiology Research Institute
Cedars-Sinai Medical Center
Associate Professor, Medicine
University of California, Los Angeles
David Geffen School of Medicine
Los Angeles, CA
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 21, 2019 through January 20, 2020.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 5 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationship(s):
Benjamin Cohen, MD, MAS
Consulting Fee: AbbVie, Alfasigma, Allergan, Celltrion, Ferring, Grifols, Janssen
Contracted Research: AbbVie
Jean-Frédéric Colombel, MD
Consulting Fee: AbbVie, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Celgene, Celltrion, Enterome, Ferring, Genentech, Gilead, Janssen, Lilly, Medimmune, Merck, Nextbiotix, Novartis, Otsuka, Pfizer, Protagonist, Second Genome, Seres, Shire, Takeda, Theradiag, Zealand Pharma
Speakers Bureau: AbbVie, Celgene, Ferring, Takeda
Ownership Interest: Genefit, Intestinal Biotech Development
Peter D.R. Higgins, MD, PhD, MSc
Contracted Research: Arena Pharmaceuticals
Gary R. Lichtenstein, MD
Royalty: SLACK Incorporated
Consulting Fee: Abbott/AbbVie, Actavis, Alaven, Cellcuetix, Celgene, Ferring, Gilead, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Prometheus, Romark, Salix/Valeant, Santarus/Receptos/Celgene, Shire, UCB
Contracted Research: Celgene, Salix/Valeant, Santarus/Receptos/Celgene, Shire, UCB
Consulting Fee (paid to institution): Pfizer, Takeda
Research Grant (paid to institution): Janssen Orthobiotech
Author Honoraria: McMahon Publishing, UptoDate
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
Dermot McGovern, MD, FRCP, PhD
Consulting Fee: Gilead, Pfizer
Contracted Research: Janssen
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com